PubMed · 2026-05-13
Scientists have developed a new generation of protein-based medicines that are more powerful and versatile than ever before, using advanced engineering and multiple types of living cells—including plant-based systems—to produce them more safely and at larger scales.
Plant-based production platforms have emerged alongside microbial and mammalian systems as viable hosts for manufacturing complex recombinant protein therapeutics.
Next-generation protein formats—including bispecific antibodies, nanobodies, and self-assembling biomaterials—now target oncology, inflammation, and metabolic disorders.
Regulatory frameworks are actively adapting to accelerate approval of personalized and complex biologics, with decentralized manufacturing models beginning to emerge.